About SeLux Diagnostics
SeLux Diagnostics is a company based in Cambridge (United States) founded in 2014. SeLux Diagnostics has raised $161.01 million across 11 funding rounds from investors including NIH, HHS and RA Capital. SeLux Diagnostics offers products and services including Selux NGP System, Selux Analyzer, and Selux Panels. SeLux Diagnostics operates in a competitive market with competitors including Cepheid, Day Zero Diagnostics, Specific Technologies, SpinDiag and InSilixa, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Selux Diagnostics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$161.01 M (USD)
in 11 rounds
-
Latest Funding Round
$48 M (USD), Series C
Feb 01, 2024
-
Investors
NIH
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SeLux Diagnostics
SeLux Diagnostics offers a comprehensive portfolio of products and services, including Selux NGP System, Selux Analyzer, and Selux Panels.
Provides rapid antibiotic susceptibility testing for infectious diseases.
Offers precise cell health analysis for fast AST results.
Facilitates comprehensive menu for antimicrobial resistance testing.
People of SeLux Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of SeLux Diagnostics
SeLux Diagnostics has successfully raised a total of $161.01M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $48 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SeLux Diagnostics
SeLux Diagnostics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Active, long-term growth equity investments are provided globally.
|
Locked | Locked | Locked | |
|
Private equity investments are directed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for SeLux Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SeLux Diagnostics
Investment portfolio details for SeLux Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SeLux Diagnostics
Detailed financials for SeLux Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Selux Diagnostics Comparisons
Peer comparison for SeLux Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SeLux Diagnostics
SeLux Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Day Zero Diagnostics, Specific Technologies, SpinDiag and InSilixa, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Genome sequencing diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Detection and antibiotic susceptibility testing for blood infections are provided.
|
|
| Locked | Locked | Locked |
Point-of-care systems for screening drug-resistant pathogens are developed.
|
|
| Locked | Locked | Locked |
Develops innovative point-of-care diagnostics using semiconductor-based CMOS biochip technology.
|
Detailed competitors of SeLux Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Selux Diagnostics
Complete news archive for SeLux Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SeLux Diagnostics
SeLux Diagnostics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
SeLux Diagnostics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
SeLux Diagnostics is a funded company, having raised a total of $161.01M across 11 funding rounds to date.
Developer of alternatives to traditional ELISA assays. The company claims that its novel assay replaces the use of enzymes with an alternative that makes it more sensitive and faster than traditional ELISAs. Applications include point-of-care assays that have sensitivity similar to clinical laboratories.
SeLux Diagnostics's top competitors include Cepheid, Day Zero Diagnostics and Specific Technologies.
SeLux Diagnostics offers Selux NGP System, Selux Analyzer, and Selux Panels.
SeLux Diagnostics has 7 investors. Key investors include NIH, HHS, RA Capital, Northpond Ventures, and Sands Capital.